Introduction
Disruption of proapoptotic and cell survival pathways is common in acute myelogenous leukemia (AML), which potentially accounts for the resistance to chemotherapy and treatment failure. 1, 2 The Ras/Raf/MEK/ERK pathway is known to control cell proliferation and cell survival, two activities that have a direct impact on tumor promotion and progression. 3, 4 We have previously reported that ERK is constitutively activated in more than 50% of primary AMLs but not in normal CD34 þ progenitors 5 and that constitutive ERK activation is an independent prognostic factor for survival in AML (Kornblau et al, Blood 2001; 98: 716a). These observations prompted us to consider the MEK/ERK pathway as a potential therapeutic target in this disease.
Several small molecule inhibitors that target specific components of the MEK/ERK pathway are available, allowing the opportunity to test the biological contribution of these targets to cell survival. Some of these small molecules are currently under clinical development, 6 following pharmacodynamic and preclinical studies that have established antitumor effects of these inhibitors. 7, 8 One such agent, CI-1040, is an orally active small molecule that is noncompetitive with ATP, and a highly selective inhibitor of MEK. CI-1040 is presently undergoing phase II evaluation in cancer patients. 8 We have observed that CI-1040 inhibited cell proliferation and survival in human leukemia cell lines. No studies have been conducted to examine the effects of CI-1040 in relapsed/refractory AML cells.
Materials and methods

Cell lines and primary samples
Human AML cell lines (OCI-AML3, NB4) were maintained in RPMI 1640 medium containing 10% heat-inactivated fetal calf serum (FCS), 1 mM L-glutamine and 50 mg/ml penicillin/streptomycin (Gemini Bio-Products, Woodland, CA, USA). Normal bone marrow (NBM) samples were obtained by aspiration from the posterior iliac crest of 12 healthy donors. Peripheral blood CD34 þ cells (PB CD34 þ ) were collected by leukapheresis procedures from four normal volunteers who had received rhG-CSF. PB and BM aspirate samples were obtained from 42 AML patients. The study comprised 26 male and 16 female subjects, 16 patients were studied at diagnosis and 26 had relapsed/ refractory leukemias. (see Supplementary Information Table 1 ) Donors and patients gave informed consent according to institutional guidelines at The University of Texas MD Anderson Cancer Center.
Cell culture and primary cell isolation
For all in vitro experiments, cells were harvested in log-phase growth, washed and seeded at the appropriate concentration in the presence of CI-1040 (Pfizer Global Research and Development, Ann Arbor, MI, USA) or in an equal volume of the vehicle DMSO. Mononuclear cells (MNCs) were separated from PB and BM samples obtained from healthy donors and AML patients, by differential Ficoll-Hypaque (Sigma Chemical Co. St Louis, MO, USA) centrifugation. CD34 þ cells were highly purified, by Mini Macs highgradient magnetic separation column (Miltenyi Biotec, Auburn, CA, USA) according to the manufacturer's instructions. Assessment of cell numbers and viability was made by Trypan blue exclusion and counting using a hemacytometer. Cells used for in vitro studies were resuspended in RPMI 1640 supplemented with 10% FCS, 1% L-glutamine, and 1% penicillin-streptomycin. The numbers were adjusted to a starting concentration of 1.0 Â 10 6 /ml, and cultured at 371C in an atmosphere of 5% CO 2 with CI-1040 at 3 mM or with vehicle (DMSO).
p-ERK activation
To examine the efficacy of CI-1040, we investigated its ability to block ERK activation after stimulation with phorbol-12 myristate 13-acetate (PMA) (Sigma). An aliquot of cells, for each cell line, at different time points and for each culture condition, was treated with 15 mM PMA for 3 min at 371C and used as positive control of p-ERK activation. Similarly, according to cell availability, PMA-induced ERK activation was performed on aliquots of primary cells from AML samples collected at time 0 and after liquid culture with and without CI-1040 by exposure to 15 mM PMA for 3 min at 371C.
Measurement of p-ERK expression by flow cytometry (FCM)
p-ERK expression was evaluated by FCM using a previously described procedure 9 with modifications. Briefly, PMA-stimulated and unstimulated cells were fixed using 2% formaldehyde (Polysciences Inc., Warrington, PA, USA) at 371C for 10 min. Following fixation, the samples were resuspended in 90% icecold methanol (Fisher Scientific, Fair Lawn, NJ, USA) and kept on ice for 30 min. Cells suspensions were centrifuged and washed once with PBS containing 4% bovine serum albumin (BSA) and then labeled with the primary monoclonal antibody (mAb) specific for p-ERK (clone E10, Cell Signaling Technology Inc., Beverly, MA, USA) for 30 min at 41C. An irrelevant mouse antibody of the appropriate subclass was used as a negative control to determine background fluorescence. After one wash, cells were incubated with a goat antibody fragment anti-mouse Ig conjugated with phycoerythrin (PE) (Biosource, Camarillo, CA, USA) for 30 min at 41C, according to the manufacturer's recommendation and samples were measured immediately. p-ERK expression was measured in selected subpopulations of PMA-stimulated or unstimulated cells with mAb directed against surface antigens according to the procedure described above.
Western blot analysis p-ERK expression was verified by Western blot analysis as described previously. 5 Briefly, PMA-stimulated and unstimulated cells were washed twice and lysed for 30 min on ice in a solution containing 10 mM NaF, 1 mM Na 3 VO 4 , 150 mM NaCl, 1 mM MgCl 2 , 1 mM CaCl 2 , 0.1% NaN 3 , 10 mM iodoacetamide, 3 mM PMSF, and 1% Triton X-100 supplemented with protease inhibitor cocktail (Roche Diagnostic Corp., Indianapolis, IN, USA). Proteins were subjected to SDS-PAGE, transferred to Hybond-P membranes (Amersham Pharmacia Biotech, Little Chalfont, England), and immunoblotted with the same p-ERKspecific mAb used for FCM analysis. Membranes were then probed with an HRP-conjugated secondary antibody and reacted with ECL reagent (Amersham). Signals were detected by phosphoimager (Storm 860, Molecular Dynamics Version 4.0; Molecular Dynamics, Sunnyvale, CA, USA) and quantified by Scion Image software (Scion Corp., Frederick, MD, USA). In order to normalize the levels of p-ERK, samples were probed with a mAb recognizing p42 MAPK (clone D-2, Santa Cruz Biotechnology Inc., CA, USA).
Apoptosis and cell-cycle analysis
Cells were examined over a culture period of 24-96 h using Annexin V to detect phosphatidylserine externalization on the plasma membrane. Cells were washed twice with PBS and resuspended in binding buffer (10 mM Hepes/NaOH pH 7.4, 140 mM NaCl, 2.5 mM CaCl 2 ; Sigma Chemical Co.). FITCconjugated Annexin V (Annexin V-FITC) (Roche) was added at a final concentration of 1 mg/ml. The mixture was incubated at room temperature for 15 min in the dark prior to flow cytometric analysis. Membrane integrity was simultaneously assessed by propidium iodide (PI) (0.25 mg/ml) exclusion.
PI staining for cell-cycle distribution and DNA degradation analysis: cells were fixed in ice-cold ethanol (70% v/v) for 1 h at 41C and stained with PI (25 mg/ml PI, 180 U/ml RNase, 0.1% Triton X-100, and 30 mg/ml polyethylene glycol in 4 mM citrate buffer, pH 7.8; Sigma).
FCM and FACS analysis
FCM analysis was conducted using a FACScalibur flow cytometer (Becton Dickinson, San Jose, CA, USA) operated at 488 nm, which detects green (FITC/CD surface antigens, Ps/ AxV), red (PE/pERK1/2 and PI), and with the 4670 nm band pass filter (APC/CD surface antigens) fluorescence. Data acquisition and analysis (10 000-20 000 events) was performed with the CellQuestPro software (Becton Dickinson). Cell-cycle distribution was analyzed using the ModFit LT software (Verity Software House, Topsham, ME, USA).
Statistical analysis
p-ERK expression evaluated by FCM was analyzed using the Kolmogorov-Smirnov statistic test (D), which allows the objective and accurate identification of small differences in fluorescence intensity. Samples with a D40.1 were considered positive.
The two-sided Student's t-test was used to evaluate the significance of differences between groups. Results are expressed as the mean7standard error of the mean (s.e.m.).
Results
Evaluation of p-ERK levels in normal CD34
þ cells
The levels of p-ERK were evaluated in highly purified normal CD34 þ cells harvested from 16 donors. BM CD34 þ cells were studied under steady-state conditions (10 samples) and after G-CSF-mobilization (two samples). Steady-state BM CD34 
þ cells), suggesting that the effects on p-ERK levels were not only due to G-CSF stimulation, but also vary in different compartments (Figure 1 ).
p-ERK levels in primary AML samples
We investigated the constitutive p-ERK levels in primary blast cells taken from AML patients. For these experiments, cells were separated and analyzed immediately after harvesting. We found constitutive ERK phosphorylation in 83.3% (35/42) cases, with a mean D value of 0.3270.04, confirming that the majority of AML shows enhanced activity of this pathway. Seven cases 
Effects of CI-1040 on p-ERK levels in AML cells
We then investigated the effects of CI-1040 on AML cell lines. CI-1040 completely inhibited ERK phosphorylation in NB4 cells, which exhibited constitutive ERK phosphorylation, after 24 h of exposure (Figure 4 (Figure 5b) .
We then compared the effects of CI-1040 on p-ERK at different stages of disease. A significant reduction in p-ERK was observed in both diagnostic (P ¼ 0.0075) and relapsed/refractory (P ¼ 0.0031) AML samples ( Figure 6 ).
Effects of the specific MEK inhibitor CI-1040 on apoptosis
Treatment of OCI-AML3 cells with CI-1040 induced a timedependent increase of apoptotic cells as demonstrated by hypodiploid DNA content, which appeared to require at least 48 h (Figure 7) .
However, in primary patient samples, an increase in apoptotic cells was observed in only one sample obtained from a chemotherapy refractory patient. Annexin V þ cells increased after 24 h in the presence of inhibitor (11.86% in DMSO vs 31.62% in CI-1040), and increased 6.2-fold after 72 h (8.58 vs 53.36%) (data not shown). Notably, in the same patients, we observed strong inhibition of p-ERK levels at 3 mM CI-1040 (475% inhibition by flow cytometry, and complete inhibition by Western blotting analysis). However, as noted, all other samples did not enter apoptosis following MEK inhibition with CI-1040.
Discussion
We report the activation of ERK in primary cells from patients with AML at diagnosis or with refractory or relapsed disease by FCM and demonstrate that a small molecule inhibitor of MEK/ ERK, CI-1040, profoundly decreased the expression of p-ERK without inducing apoptosis.
Several groups have described the use of phospho-specific antibodies to detect phospho-proteins by FCM. [9] [10] [11] [12] [13] [14] We describe here optimized conditions for p-ERK quantitation in primary patients cells by FCM (see Supplemental Information).
The observed lack of constitutive ERK activation in steadystate normal hematopoietic progenitor supports the notion that therapeutic strategies targeting MEK/ERK signaling pathway would selectively affect leukemic cells. 5, 15, 16 Previous studies suggested that circulating progenitor cells differ from their BM counterparts with respect to cell-cycle characteristics and proliferative response to cytokines, [17] [18] [19] [20] which is also reflected in our finding of differential ERK phosphorylation and may reflect effects mediated by the microenvironment.
The finding that a high percentage (83.3%) of AML samples in our study contains activated ERK is remarkable. In comparison 
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Figure 2
Constitutive p-ERK expression in primary AML samples. p-ERK expression in primary AML samples was analyzed by FCM as described in Materials and methods. Out of the 42 samples analyzed, 35 showed constitutive expression of p-ERK. There was no difference between samples from newly diagnosed and relapsed/refractory AML samples.
p-ERK expression in refractory/relapsed AML samples MR Ricciardi et al with previous reports 5, 21, 22 using Western blotting for analysis of p-ERK, we examined here, for the first time, clinical samples by FCM. FCM allows to better identify and quantify phosphoproteins in subpopulations of cells with undetectable or very low expression levels as compared to other methods, because of its ability to measure single cells and not just population averages. This ability is further maximized by the use of Kolmogorov-Smirnov analysis, which is suited to identify quantitatively such small subpopulations. No correlation between constitutive p-ERK expression and stage of disease, or between CI-1040-induced p-ERK inhibition and disease status was found. Results therefore suggest that prior therapy does not select clones with increased levels of p-ERK.
We noted that inhibition of ERK phosphorylation in AML cell lines was associated with inhibition of cell growth. 5 Consistent with the role of RAS/MAPK signaling in the G 1 /S transition 3 
Figure 4
MEK blockade inhibits p-ERK expression in human leukemia cell line. Histograms show a representative experiment of constitutive p-ERK expression and pharmacodynamic inhibition in NB4 cells. Filled plot indicates isotype control. Cells were seeded at a starting concentration of 3 Â 10 5 cells/ml, and cultured in the presence of vehicle control (DMSO) or CI-1040 at the indicated concentrations for up to 24 h. Viable cells were counted by Trypan blue dye exclusion at the indicated time points and processed for FCM analysis as described in Materials and methods. CI-1040 inhibited p-ERK expression after 24 h of liquid culture.
Figure 3
Correlation between FCM and Western blot analysis of p-ERK in OCI-AML3 and primary AML cells. Cells were processed for FCM and Western blot analysis as described in Materials and methods. Results obtained with both techniques were comparable.
p-ERK expression in refractory/relapsed AML samples MR Ricciardi et al through post-translational regulation of p27 Kip1 , 23, 24 CI-1040 induced G 1 cell-cycle arrest in AML cell lines, associated with induction of apoptosis. In contrast, in primary AML, CI-1040 decreased p-ERK expression without effects on cell survival. Previous studies using the MEK inhibitor PD98059 reported that inhibition of p-ERK was coupled with the induction of apoptosis. 5, 22 We failed to demonstrate apoptosis induction after 24 h and even after extended incubation with 3 mM CI-1040. Only in a single sample, p-ERK inhibition was associated with induction of apoptosis.
Preclinical studies demonstrated antitumor activity of CI-1040 in breast, pancreas, and colon tumor models and this activity has been shown to correlate with its inhibition of p-ERK 8 Consistent with the role of ERK signaling in growth factorstimulated cell proliferation, the ability of MEK/ERK inhibitors PD98059 and U0126 to antagonize cell-cycle progression was reported. 25, 26 However, Kamakura et al 27 suggested that these two inhibitors also prevent activation of MEK5/ERK5, raising the possibility that their antiproliferative effects are due to inhibition of both ERK1/2 and ERK5 signaling. Compared with the other kinase inhibitors, PD185342 (CI-1040) appears to be highly specific for MEK1/2, with very low activity against MEK5, 28, 29 which may explain the lack of apoptosis induction. Other signaling pathways could also contribute to sustained AML blast survival. Xu et al 30 and Zhao et al 31 demonstrated that the PI3K pathway is deregulated in primary AML cells and that PI3K inhibition resulted in decreased survival, raising the possibility of signaling redundancy. 30 With the exception of STI571, there is little evidence that the inhibition of any kinase alone, although effective in vitro, leads to useful antitumor effects in the clinical setting. However, several preclinical studies have already demonstrated synergistic effects of kinase inhibitors in combination with standard chemotherapy, 6, 32, 33 while others have reported apparent failure of combination strategies. 34 This raises the question of how to optimize the design of combination studies and when in the p-ERK expression in refractory/relapsed AML samples MR Ricciardi et al course of tumor evolution it is most likely to have a measurable impact. 6 The integration of different signal transduction pathways is decisive for cell survival. 35 As a consequence, combinations of inhibitors that target crosstalking survival pathways may be more effective than single agents. Activated PI3K/Akt and Raf/ MEK/ERK pathways can synergize in the abrogation of cytokine dependence of hematopoietic cells. 36 Simultaneous inhibition of Bcl-2 and MEK/ERK signaling (by CI-1040) resulted in highly synergistic reduction of cell growth and induction of apoptosis in AML cell lines with constitutive ERK activation 37, 38 and may be a strategy to convert the cytostatic effects of MAPK inhibition into apoptotic responses.
In conclusion, our data suggest that pharmacological inhibition of a single molecular target in AML might not result in antitumor activity. More likely, targeting additional signaling pathways that act in parallel or downstream of one another could be more effective, and predictive pharmacodynamic assays aimed at selecting potentially sensitive patient populations may be critical for developing targeted combination therapies. 38 
Figure 7
CI-1040 induces time-dependent apoptosis in OCI-AML3 cells. OCI-AML3 cells growing exponentially were cultured in the presence of vehicle control (DMSO) or CI-1040. Cells were harvested at different time points, washed, fixed in 70% ethanol, and stained for DNA content by PI. Apoptosis was evaluated as percentage of cells with hypodiploid DNA content. Results are expressed as net apoptosis induction.
p-ERK expression in refractory/relapsed AML samples MR Ricciardi et al
